Anta Sports Expands Global Footprint With Strategic Puma Stake 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SAN DIEGO, Feb. 27, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced that Dr. Henry Li, a respected expert in preclinical pharmacology, will present a webinar showing data derived from CrownBio’s large-scale immunotherapy screening platform, MuScreen™. The webinar is scheduled for Thursday, March 1, 2018 at 11am EST (5pm CEST).
CrownBio recently completed a comprehensive immunoprofiling study to fast-track the in vivo screening of a panel of 12 commonly used syngeneic models against PD-1/PD-L1 blockade. The analysis of this large study, using both efficacy and immunophenotyping (by flow cytometry on tumor infiltrating immune cells), was conducted for both baseline and pharmacodynamic readouts. The results help address numerous scientific/technical challenges, including a multitude of characteristics for individual syngeneic models and the variations associated with studies using syngeneic models. Attendees will discover how to design and utilize a large-scale, staggered syngeneic platform to address key immuno-oncology questions, improve efficiency and reproducibility of immunotherapy development, all while reducing costs.
“CrownBio strives to provide scientists with predictive solutions that surpass traditional approaches and provide decision making during drug development,” said Dr. Henry Li, CrownBio’s Sr. Vice President of Scientific Research and Innovation. “I am looking forward to presenting conclusive data that shows the utility of our MuScreen platform to accelerate development of immunotherapeutic agents efficiently and cost-effectively.”
Learn more about CrownBio’s large-scale immunotherapy screening platform and sign up to attend the webinar here.
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
